ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA grants priority review to Biologics License Application for sutimlimab
May 21, 2020The FDA has granted priority review of the Biologics License Application for sutimlimab to treat haemolysis in patients with cold agglutinin disease (CAD). -
Sutimlimab shows promise for hard-to-treat, rare blood disorder
December 19, 2018In a first-in-human clinical trial reported today in Blood, the investigational drug sutimlimab appeared to be effective in treating cold agglutinin disease, a rare chronic blood disorder for which there are currently no approved treatments.
Pharma Sources Insight January 2025
